GlassScriptPhysician profile
George M Bright
NPI 1235181702
$283,987.03
in general payments reported to CMS, 2019-2025
27 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Adolescent Medicine (Family Medicine) providers received nationally (typical 2025 total: $135).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72K · 2020: $31K · 2021: $39K · 2022: $59K · 2023: $41K · 2024: $26K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Consulting Fee: $23K · Food and Beverage: $8,874 · Travel and Lodging: $2,821 · Honoraria: $800 · Education: $61.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,870.40 |
| Consulting Fee | $22,620.00 |
| Food and Beverage | $8,874.31 |
| Travel and Lodging | $2,821.26 |
| Honoraria | $800.00 |
| Education | $61.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $140,972.56 | 2019-2024 | Jornay Pm |
| Neos Therapeutics, LP | $77,365.56 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt, Exxua |
| Tris Pharma INC | $21,962.96 | 2023-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Corium, LLC | $21,949.19 | 2022-2025 | Azstarys, Azstarys |
| Aytu Biopharma, INC. | $13,666.23 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,547.20 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,205.31 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Eton Pharmaceuticals, INC. | $1,000.00 | 2025 | Khindivi, Increlex, Alkindi |
| Mdd US Operations, LLC | $587.38 | 2019 | |
| Neurocrine Biosciences, INC. | $570.34 | 2022-2024 | Ingrezza |
| Lundbeck LLC | $523.05 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $468.02 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $409.28 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $321.85 | 2021-2025 | Qelbree, Qelbree |
| Abbvie INC. | $239.89 | 2023-2025 | Vraylar |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $236.29 | 2022-2024 | Loreev Xr, Gralise |
| Eisai INC. | $189.94 | 2020-2022 | |
| Orexo US, INC. | $181.30 | 2019 | |
| Idorsia Pharmaceuticals US INC | $174.83 | 2023-2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $152.91 | 2025 | Jornay Pm |
| Indivior INC. | $108.46 | 2024-2025 | Sublocade |
| Merck Sharp & Dohme LLC | $56.89 | 2022-2023 | Belsomra |
| Alkermes, INC. | $39.01 | 2022-2024 | Vivitrol |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.31 | 2020 | |
| Shire North American Group INC | $14.79 | 2019 | |
| Kaleo, INC. | $14.51 | 2023 | Auvi-Q |
| Janssen Pharmaceuticals, INC | $13.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Bright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.